|
|
PRESS RELEASE
PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN PROGRESSIVE FORMS OF MULTIPLE
SCLEROSIS IN THE JOURNAL NEUROLOGY®: NEUROIMMUNOLOGY & NEUROINFLAMMATION
Paris, 22 February, 2022, 6pm CET
AB Science SA Euronext FR0010557264 AB today announced publication of results from its positive
pivotal phase 3 trial of masitinib in progressive forms of multiple sclerosis in... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
PUBLICATION DE L’ETUDE CLINIQUE PIVOT DE PHASE 3 DU MASITINIB DANS LES FORMES PROGRESSIVES
DE LA SCLÉROSE EN PLAQUES DANS LA REVUE NEUROLOGY®: NEUROIMMUNOLOGY &
NEUROINFLAMMATION
Paris, 22 février 2022, 18h
AB Science SA Euronext FR0010557264 AB annonce aujourdhui la publication des résultats positifs de
son étude pivot de phase 3 du masitinib dans les formes... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
CLARIFICATION FOLLOWING THE FEBRUARY 11, 2022 PUBLIC HEARING OF THE ENFORCEMENT COMMITTEE
OF THE FRENCH MARKET REGULATOR AMF
Paris, 12 February, 2022, 8.30pm CET
AB Science SA Euronext FR0010557264 AB wishes to provide the following clarifications, following press
articles published after the public hearing of the Enforcement Committee of the French market regulator
AMF on... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
AB SCIENCE A RECU L’AUTORISATION DE L’ANSM POUR INITIER UNE ETUDE DE PHASE II CHEZ LES PATIENTS
ATTEINTS DU SYNDROME D’ACTIVATION DES MASTOCYTES SEVERE
Paris, 19 janvier 2022, 18h
AB Science SA Euronext FR0010557264 AB annonce aujourd’hui avoir reçu l’autorisation de l’ANSM pour
initier une étude de phase II AB20006 chez les patients atteints du syndrome... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
AB SCIENCE HAS BEEN GRANTED AUTHORIZATION TO INITIATE PHASE II STUDY IN PATIENTS WITH SEVERE
MAST CELL ACTIVATION SYNDROME BY THE FRENCH HEALTH AUTHORITY ANSM
Paris, 19 January, 2022, 6pm CET
AB Science SA Euronext FR0010557264 AB today announces that it has been authorized by the French
Medicine Agency, ANSM, to initiate a Phase II study AB20006 in patients with severe mast... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
AB SCIENCE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 TRIAL OF MASITINIB’S ANTIVIRAL ACTIVITY
AGAINST THE SARSCoV2 COVID19 VIRUS
Paris, 29 November, 2021, 8.45pm CET
AB Science SA Euronext FR0010557264 AB today announced that the first patient has been dosed in the
phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
AB SCIENCE ANNONCE LE RECRUTEMENT DU PREMIER PATIENT DANS l’ETUDE DE PHASE 2 EVALUANT
L’ACTIVITE ANTIVIRALE DU MASITINIB CONTRE LE VIRUS SARSCoV2 COVID19
Paris, 29 novembre 2021, 20h45
AB Science SA Euronext FR0010557264 AB annonce aujourdhui le recrutement du premier patient dans
létude de phase 2 évaluant lactivité antivirale du masitinib chez les patients... Lire le communiqué |
|
| |
|
| |
